MA52617A - Biomarqueurs sanguins de l'accident vasculaire cérébral - Google Patents

Biomarqueurs sanguins de l'accident vasculaire cérébral

Info

Publication number
MA52617A
MA52617A MA052617A MA52617A MA52617A MA 52617 A MA52617 A MA 52617A MA 052617 A MA052617 A MA 052617A MA 52617 A MA52617 A MA 52617A MA 52617 A MA52617 A MA 52617A
Authority
MA
Morocco
Prior art keywords
cerebral vascular
blood biomarkers
vascular accident
accident
biomarkers
Prior art date
Application number
MA052617A
Other languages
English (en)
French (fr)
Inventor
Emmanuelle Genin
Serge Timsit
Original Assignee
Centre Hospitalier Regional Et Univ De Brest
Francais Du Sang Ets
Inst Nat Sante Rech Med
Univ Bretagne Occidentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional Et Univ De Brest, Francais Du Sang Ets, Inst Nat Sante Rech Med, Univ Bretagne Occidentale filed Critical Centre Hospitalier Regional Et Univ De Brest
Publication of MA52617A publication Critical patent/MA52617A/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA052617A 2018-05-16 2019-05-16 Biomarqueurs sanguins de l'accident vasculaire cérébral MA52617A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18305600 2018-05-16

Publications (1)

Publication Number Publication Date
MA52617A true MA52617A (fr) 2021-03-24

Family

ID=62386311

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052617A MA52617A (fr) 2018-05-16 2019-05-16 Biomarqueurs sanguins de l'accident vasculaire cérébral

Country Status (13)

Country Link
US (1) US12247257B2 (https=)
EP (1) EP3794355A1 (https=)
JP (2) JP7463351B2 (https=)
KR (1) KR20210049026A (https=)
CN (1) CN112424609A (https=)
AU (1) AU2019270404B2 (https=)
BR (1) BR112020023259A2 (https=)
CA (1) CA3100171A1 (https=)
IL (1) IL278666B2 (https=)
MA (1) MA52617A (https=)
MX (1) MX2020012297A (https=)
SG (1) SG11202011369VA (https=)
WO (1) WO2019219831A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220093267A1 (en) * 2019-01-22 2022-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Noninvasive real-time patient-specific assessment of stroke severity
CN114107487B (zh) * 2021-12-23 2024-01-09 太原市精神病医院 一种可用于诊断脑卒中的产品
JP2023111774A (ja) * 2022-01-31 2023-08-10 国立研究開発法人国立循環器病研究センター 再灌流療法の適用を決定するバイオマーカー
CN116705296B (zh) * 2023-06-06 2024-09-13 中国科学院深圳先进技术研究院 一种基于常规mri序列对gbm患者进行风险分层的方法及系统
WO2025151599A1 (en) * 2024-01-09 2025-07-17 Morehouse School Of Medicine Rna-based method for stroke assessment and treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU2002241520A1 (en) * 2000-11-28 2003-03-03 University Of Cincinnati Blood assessment of injury
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
US9410204B2 (en) 2012-01-07 2016-08-09 The Regents Of The University Of California Biomarkers for diagnosing ischemia
US20150274815A1 (en) * 2012-09-25 2015-10-01 The United States of America, as represented by the Secretary, Department of Health & Human Servic Treatment of central nervous system (cns) injury
JP2016507235A (ja) * 2013-02-01 2016-03-10 ウエストバージニア ユニバーシティWest Virginia University 脳卒中症状の発症の時点を決定するためのバイオマーカーアルゴリズムおよび方法
US11021750B2 (en) * 2013-10-13 2021-06-01 The Research Foundation For State University Of Newyork Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
CN108291330A (zh) * 2015-07-10 2018-07-17 西弗吉尼亚大学 卒中和卒中严重性的标志物
US20190311789A1 (en) * 2016-10-03 2019-10-10 West Virginia University Computer implemented discovery of biomarkers for blood brain barrier disruption

Also Published As

Publication number Publication date
KR20210049026A (ko) 2021-05-04
EP3794355A1 (en) 2021-03-24
AU2019270404B2 (en) 2025-04-17
SG11202011369VA (en) 2020-12-30
AU2019270404A2 (en) 2020-12-17
IL278666B1 (en) 2025-02-01
US20210214793A1 (en) 2021-07-15
JP2021523744A (ja) 2021-09-09
AU2019270404A1 (en) 2020-12-10
MX2020012297A (es) 2021-03-25
JP2024075761A (ja) 2024-06-04
IL278666A (en) 2020-12-31
BR112020023259A2 (pt) 2021-02-23
US12247257B2 (en) 2025-03-11
JP7463351B2 (ja) 2024-04-08
CA3100171A1 (en) 2019-11-21
WO2019219831A1 (en) 2019-11-21
IL278666B2 (en) 2025-06-01
CN112424609A (zh) 2021-02-26

Similar Documents

Publication Publication Date Title
MA52617A (fr) Biomarqueurs sanguins de l'accident vasculaire cérébral
EP3442612A4 (en) MEDIUM-TREATED BALLOON CATHETER FOR BODY LIQUIDS
EP3841989C0 (en) INTRAVASCULAR CATHETER
EP4135818A4 (en) CATHETER CONSTRUCTION
MA52665A (fr) Procédé d'amélioration de l'expression de l'hémoglobine foetale
EP3482201A4 (en) EARLY DIAGNOSIS OF INFECTIONS
MA49141A (fr) Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
EP3784363A4 (en) DEVICE AND METHOD FOR SEPARATION OF BLOOD COMPONENTS
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
EP3883553A4 (en) ARYL ANILINE AND HETEROARYL ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CANCER
IL280991A (en) Platelet count-agnostic methods of treating myelofibrosis
EP3331526A4 (en) NICOTIN-DEGREEING ENZYMES FOR THE TREATMENT OF NICOTINE DEPENDENCE AND NICOTINE POISONING
EP3326640A4 (en) APPLICATIONS OF MUSHROOM ADHESIVE PRODUCTS IN THE TREATMENT AND PREVENTION OF DISEASES RELATED TO MELANINE
EP3735209A4 (en) TREATMENT OF THE PROGRESSION OF MYOPOIA
EP3936251A4 (en) VEHICLE BODY STRUCTURE
EP3632431A4 (en) AGENTS FOR PREVENTING OR TREATING BRAIN ATROPHY
EP3833435A4 (en) DETERMINATION OF PARKINSON'S DISEASE
EP3733177A4 (en) COMPOSITION FOR CORNEAL PROTECTION
EP3551666A4 (en) VARIANTS OF ANTIBODIES CROSSING THE HEMATOENCEPHALIC BARRIER AND THEIR USES
EP3641846A4 (en) HEMOFILTER FOR IN-VIVO BLOOD FILTRATION
EP4415796A4 (en) IMPROVED CEREBRAL ANGIOGRAPHY CATHETER
IL270927B (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
EP3912890A4 (en) VEHICLE BODY STRUCTURE
EP3675715A4 (en) Sensing strategies for health assessment of osseointegrated prostheses
LT3794148T (lt) Aneurizmos arba vėžio diagnozės būdai